These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 32669430)

  • 61. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease.
    Khurana S; Loving CL; Manischewitz J; King LR; Gauger PC; Henningson J; Vincent AL; Golding H
    Sci Transl Med; 2013 Aug; 5(200):200ra114. PubMed ID: 23986398
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design.
    Wei CJ; Boyington JC; Dai K; Houser KV; Pearce MB; Kong WP; Yang ZY; Tumpey TM; Nabel GJ
    Sci Transl Med; 2010 Mar; 2(24):24ra21. PubMed ID: 20375007
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy.
    Kim SM; Kim YI; Park SJ; Kim EH; Kwon HI; Si YJ; Lee IW; Song MS; Choi YK
    J Virol; 2017 Mar; 91(6):. PubMed ID: 28077631
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.
    Wang Y; Wu J; Xue C; Wu Z; Lin Y; Wei Y; Wei X; Qin J; Zhang Y; Wen Z; Chen L; Liu GD; Cao Y
    Antiviral Res; 2017 Jul; 143():97-105. PubMed ID: 28408133
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
    Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Immunogenicity and Protection Against Influenza H7N3 in Mice by Modified Vaccinia Virus Ankara Vectors Expressing Influenza Virus Hemagglutinin or Neuraminidase.
    Meseda CA; Atukorale V; Soto J; Eichelberger MC; Gao J; Wang W; Weiss CD; Weir JP
    Sci Rep; 2018 Mar; 8(1):5364. PubMed ID: 29599502
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Monovalent H5 vaccine based on epitope-chimeric HA provides broad cross-clade protection against variant H5N1 viruses in mice.
    He F; Prabakaran M; Rajesh Kumar S; Tan Y; Kwang J
    Antiviral Res; 2014 May; 105():143-51. PubMed ID: 24637255
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Multi-subtype influenza virus-like particles incorporated with flagellin and granulocyte-macrophage colony-stimulating factor for vaccine design.
    Liu WC; Liu YY; Chen TH; Liu CC; Jan JT; Wu SC
    Antiviral Res; 2016 Sep; 133():110-8. PubMed ID: 27491439
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain.
    Raymond DD; Stewart SM; Lee J; Ferdman J; Bajic G; Do KT; Ernandes MJ; Suphaphiphat P; Settembre EC; Dormitzer PR; Del Giudice G; Finco O; Kang TH; Ippolito GC; Georgiou G; Kepler TB; Haynes BF; Moody MA; Liao HX; Schmidt AG; Harrison SC
    Nat Med; 2016 Dec; 22(12):1465-1469. PubMed ID: 27820604
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pan-Influenza A Protection by Prime-Boost Vaccination with Cold-Adapted Live-Attenuated Influenza Vaccine in a Mouse Model.
    Jang YH; Kim JY; Byun YH; Son A; Lee JY; Lee YJ; Chang J; Seong BL
    Front Immunol; 2018; 9():116. PubMed ID: 29449842
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
    J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Virus-specific T cells as correlate of (cross-)protective immunity against influenza.
    Altenburg AF; Rimmelzwaan GF; de Vries RD
    Vaccine; 2015 Jan; 33(4):500-6. PubMed ID: 25498210
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Protective Immunity Against Homologous and Heterologous Influenza Virus Lethal Challenge by Immunization with New Recombinant Chimeric HA2-M2e Fusion Protein in BALB/C Mice.
    Ameghi A; Pilehvar-Soltanahmadi Y; Baradaran B; Barzegar A; Taghizadeh M; Zarghami N; Aghaiypour K
    Viral Immunol; 2016 May; 29(4):228-34. PubMed ID: 27058011
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
    Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans.
    Nachbagauer R; Choi A; Izikson R; Cox MM; Palese P; Krammer F
    mBio; 2016 Jan; 7(1):e01996-15. PubMed ID: 26787832
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Broadly neutralizing antibodies target a haemagglutinin anchor epitope.
    Guthmiller JJ; Han J; Utset HA; Li L; Lan LY; Henry C; Stamper CT; McMahon M; O'Dell G; Fernández-Quintero ML; Freyn AW; Amanat F; Stovicek O; Gentles L; Richey ST; de la Peña AT; Rosado V; Dugan HL; Zheng NY; Tepora ME; Bitar DJ; Changrob S; Strohmeier S; Huang M; García-Sastre A; Liedl KR; Bloom JD; Nachbagauer R; Palese P; Krammer F; Coughlan L; Ward AB; Wilson PC
    Nature; 2022 Feb; 602(7896):314-320. PubMed ID: 34942633
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Enhanced cross-lineage protection induced by recombinant H9N2 avian influenza virus inactivated vaccine.
    Wang Z; Li Z; Su X; Qiao Y; Fan W; Li H; Shi B; Qin T; Chen S; Peng D; Liu X
    Vaccine; 2019 Mar; 37(13):1736-1742. PubMed ID: 30797637
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Vaccination of monoglycosylated hemagglutinin induces cross-strain protection against influenza virus infections.
    Chen JR; Yu YH; Tseng YC; Chiang WL; Chiang MF; Ko YA; Chiu YK; Ma HH; Wu CY; Jan JT; Lin KI; Ma C; Wong CH
    Proc Natl Acad Sci U S A; 2014 Feb; 111(7):2476-81. PubMed ID: 24469815
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Targeting Hemagglutinin: Approaches for Broad Protection against the Influenza A Virus.
    Zhang Y; Xu C; Zhang H; Liu GD; Xue C; Cao Y
    Viruses; 2019 Apr; 11(5):. PubMed ID: 31052339
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Universal Influenza Vaccine Approaches Using Full-Length or Head-Only Hemagglutinin Proteins.
    Ross TM
    J Infect Dis; 2019 Apr; 219(Suppl_1):S57-S61. PubMed ID: 30715379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.